During the past decade, Pahl Pharmaceutical Research conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 1 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Pahl Pharmaceutical Research" are "ADHD" (1 trials), "Anxiety Disorders" (1 trials), "Attention Deficit/Hyperactivity Disorder" (1 trials) and "Methamphetamine Dependence" (1 trials). Many other conditions were trialed in "Pahl Pharmaceutical Research" in a lesser frequency.

Most popular intervention types in "Pahl Pharmaceutical Research" are "Drug" (3 trials). Other intervention types were less common.

The name of intervention was led by "CPP-109 vigabatrin" (1 trials), "Gabitril" (1 trials), "Matching Placebo" (1 trials) and "Modafinil" (1 trials). Other intervention names were less common.

The vast majority of trials in "Pahl Pharmaceutical Research" are 3 trials for "All" genders.

Currently, there are NaN active trials in "Pahl Pharmaceutical Research". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Pahl Pharmaceutical Research, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Pahl Pharmaceutical Research, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".